Literature DB >> 11958363

Iatrogenic disorders associated with conventional vs. atypical antipsychotics.

H A Nasrallah1, T Mulvihill.   

Abstract

Pharmacotherapy is an indispensable component of the management of schizophrenia and related psychotic disorders. Antipsychotic drugs are used for their efficacy in controlling the symptoms of psychosis. However, the side effects of antipsychotic drugs can have a deleterious impact on the course of the illness by inducing iatrogenic symptoms of various severity. The side effects of first-generation or conventional antipsychotic drug were often so intolerable to patients with schizophrenia that their compliance was consistently poor, leading to frequent relapse, chronicity, and impaired functioning. The second-generation (atypical) antipsychotics, introduced 40 years after the advent of the older-generation, are proving to have better outcomes in psychosis not only because of broader symptom efficacy but also because their side-effect profile is more tolerable, leading to higher compliance and fewer relapses. The authors review the side effects of the old and the new antipsychotics and conclude that the improved tolerability of the new antipsychotics is associated with greater effectiveness, not just efficacy. Differences in tolerability among the new antipsychotics are described.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11958363     DOI: 10.1023/a:1014629402131

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  3 in total

1.  Risperidone plasma levels, clinical response and side-effects.

Authors:  Michael Riedel; M J Schwarz; M Strassnig; I Spellmann; A Müller-Arends; K Weber; J Zach; N Müller; H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-29       Impact factor: 5.270

2.  Safety of carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder.

Authors:  Richard H Weisler; Amir H Kalali; Andrew J Cutler; Thomas D Gazda; Lawrence Ginsberg
Journal:  Psychiatry (Edgmont)       Date:  2008-05

3.  How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials?

Authors:  M Riedel; M Strassnig; N Müller; P Zwack; H-J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-19       Impact factor: 5.270

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.